# A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease

> **NCT07322887** · PHASE2 · RECRUITING · sponsor: **GEN İlaç ve Sağlık Ürünleri A.Ş.** · enrollment: 45 (estimated)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** SUL-238 (1500 mg t.i.d.) film-coated tablets
- **DRUG:** SUL-238 (500 mg t.i.d.) film-coated tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07322887
- **Lead sponsor:** GEN İlaç ve Sağlık Ürünleri A.Ş.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-05-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07322887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07322887, "A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07322887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*